Table 5.
Incidence and Risk of Opportunistic Infection and Herpes Zoster: THIN Cohort
| Full THIN Cohort | No Psoriasis N=954,315 |
All Psoriasis N=199,700 |
Mild Psoriasis N=187,258 |
Moderate-to-Severe Psoriasis N=12,442 |
|---|---|---|---|---|
|
| ||||
| Opportunistic Infection | ||||
|
| ||||
| Follow-up time (yrs) | ||||
| Mean (SD) | 6.5 (4.8) | 6.2 (4.7) | 6.3 (4.8) | 5.3 (4.1) |
| Median (IQR) | 5.6 (2.4, 10.0) | 5.3 (2.2, 9.7) | 5.3 (2.2, 9.7) | 4.4 (1.9, 7.9) |
|
| ||||
| Number of person-years | 6,240,165 | 1,239,794 | 1,173,285 | 66,509 |
|
| ||||
| Number (%) of opportunistic infections | 1,329 (0.14) | 236 (0.12) | 211 (0.11) | 25 (0.20) |
|
| ||||
| Incidence per 10,000 person-years (95% CI) | 2.13 (2.02, 2.25) | 1.90 (1.68, 2.16) | 1.80 (1.57, 2.06) | 3.76 (2.54, 5.56) |
|
| ||||
| Unadjusted hazard ratio (95% CI) | Reference | 0.89 (0.78, 1.02) | 0.84 (0.73, 0.97) | 1.73 (1.16, 2.57) |
|
| ||||
| Adjusted hazard ratio (95% CI)a | Reference | 0.91 (0.79, 1.04) | 0.87 (0.75, 1.00) | 1.57 (1.06, 2.34) |
|
| ||||
| Herpes Zoster | ||||
|
| ||||
| Follow-up time (yrs) | ||||
| Mean (SD) | 6.4 (4.7) | 6.1 (4.7) | 6.1 (4.7) | 5.2 (4.1) |
| Median (IQR) | 5.5 (2.3, 9.8) | 5.0 (2.1, 9.4) | 5.1 (2.1, 9.5) | 4.2 (1.9, 7.7) |
|
| ||||
| Number of person-years | 6,084,648 | 1,209,265 | 1,144,308 | 64,957 |
|
| ||||
| Number (%) of herpes zoster cases | 33,115 (3.5) | 6,537 (3.3) | 6,117 (3.3) | 420 (3.4) |
|
| ||||
| Incidence per 10,000 person years (95% CI) | 54.4 (53.8, 55.0) | 54.1 (52.8, 55.4) | 53.5 (52.1, 54.8) | 64.7 (58.8, 71.1) |
|
| ||||
| Unadjusted hazard ratio (95% CI) | Reference | 1.00 (0.97, 1.02) | 0.98 (0.96, 1.01) | 1.21 (1.10, 1.34) |
|
| ||||
| Adjusted hazard ratio (95% CI)b | Reference | 1.08 (1.05, 1.11) | 1.07 (1.05, 1.10) | 1.17 (1.06, 1.30) |
CI, confidence interval; IQR, interquartile range; SD, standard deviation; yrs, years
a
Adjusted for age, sex, BMI, smoking and drinking status, asthma/COPD, CVD, diabetes, IBD, inhaled and systemic corticosteroid use within 90 days prior to start date, hospitalization or infection within 30 days prior to start date, prior opportunistic infection, and Townsend score.
b
Adjusted for age, sex, smoking status, asthma/COPD, CVD, dementia, depression, IBD, OA, RA, SLE, systemic corticosteroid use within 90 days prior to start date, infection within 30 days prior to start date, prior herpes zoster.